Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Wen-Chi Yang is active.

Publication


Featured researches published by Wen-Chi Yang.


Journal of Biological Rhythms | 2011

Altered expression of circadian clock genes in human chronic myeloid leukemia.

Ming-Yu Yang; Wen-Chi Yang; Pai-Mei Lin; Jui-Feng Hsu; Hui-Hua Hsiao; Yi-Chang Liu; Hui-Jen Tsai; Chao-Sung Chang; Sheng-Fung Lin

Circadian clock genes use transcriptional-translational feedback loops to control circadian rhythms. Recent studies have demonstrated that expression of some circadian clock genes displays daily oscillation in peripheral tissues including peripheral blood and bone marrow. Circadian rhythms regulate various functions of human body, and the disruption of circadian rhythm has been associated with cancer development and tumor progression. However, the direct links between aberrant circadian clock gene expression and human disorders remain largely unknown. In this study, comparisons were made between the expression profiles of 9 circadian clock genes from peripheral blood mononuclear cells (PBMCs) and polymorphonuclear cells (PMNs) from 18 healthy volunteers. Peripheral blood (PB) total leukocytes from 54 healthy volunteers and 95 patients with chronic myeloid leukemia (CML) were also investigated. Similar expression profiles of all 9 circadian clock genes were observed in PBMCs and PMNs of healthy individuals. In PB total leukocytes of healthy individuals, the daily pattern of PER1, PER2, PER3, CRY1, CRY2, and CKIε expression level peaked at 0800 h, and BMAL1 peaked at 2000 h. Daily pattern expression of these 7 genes was disrupted in newly diagnosed pre—imatinib mesylate—treated and blast crisis—phase patients with CML. Partial daily pattern gene expression recoveries were observed in patients with CML with complete cytogenetic response and major molecular response. The expression of CLOCK and TIM did not show a time-dependent variation among the healthy and patients with CML. These results indicate a possible association of the disrupted daily patterns of circadian clock gene expression with the pathogenesis of CML.


Kaohsiung Journal of Medical Sciences | 2013

Urinary neutrophil gelatinase-associated lipocalin levels predict cisplatin-induced acute kidney injury better than albuminuria or urinary cystatin C levels

Hugo You-Hsien Lin; Su-Chu Lee; Sheng-Fung Lin; Hui-Hua Hsiao; Yi-Chang Liu; Wen-Chi Yang; Daw-Yang Hwang; Chi-Chih Hung; Hung-Chun Chen; Jinn-Yuh Guh

Cisplatin‐induced acute kidney injury (AKI) is a major concern among clinicians in prescribing cisplatin‐based chemotherapy. This study evaluated and compared the ability of urinary biomarkers, including urinary neutrophil gelatinase‐associated lipocalin (NGAL), cystatin C, and the urinary albumin to creatinine ratio (ACR) to predict cisplatin‐induced AKI. Thirty‐three cancer patients receiving cisplatin‐based chemotherapy were prospectively studied, including 10 (30%) who developed AKI (the study group). Changes of urinary biomarkers were compared at 4 hours, 8 hours, and 12 hours, and 1 day, 2 days, 3 days, and 4 days after cisplatin intravenous infusions (75 mg/m2) versus the baseline. There was a significant increase in urinary NGAL levels from 12 hours to 4 days (p < 0.05) compared to baseline after cisplatin infusion in the AKI group. The magnitude of these changes over time differed significantly by group (p < 0.001). The area under the receiver operating curve describing the relationship between urinary NGAL levels and AKI within 12 hours was 0.865 (95% confidence interval = 0.691–1.000). Urinary NGAL levels independently predicted AKI 12 hours after cisplatin (p = 0.045) after adjustments for age, gender, body mass index, baseline serum creatinine, and urinary total protein. Urinary NGAL levels may be an early biomarker of AKI in patients receiving cisplatin‐based treatment.


PLOS ONE | 2012

Induction of Cellular Senescence by Doxorubicin Is Associated with Upregulated miR-375 and Induction of Autophagy in K562 Cells

Ming-Yu Yang; Pai-Mei Lin; Yi-Chang Liu; Hui-Hua Hsiao; Wen-Chi Yang; Jui-Feng Hsu; Cheng-Ming Hsu; Sheng-Fung Lin

Background Cellular senescence is a specialized form of growth arrest that is generally irreversible. Upregulated p16, p53, and p21 expression and silencing of E2F target genes have been characterized to promote the establishment of senescence. It can be further aided by the transcriptional repression of proliferation-associated genes by the action of HP1γ, HMGA, and DNMT proteins to produce a repressive chromatin environment. Therefore, senescence has been suggested to functions as a natural brake for tumor development and plays a critical role in tumor suppression and aging. Methodology/Principal Findings An in vitro senescence model has been established by using K562 cells treated with 50 nM doxorubicin (DOX). Since p53 and p16 are homozygously deleted in the K562 cells, the DOX-induced senescence in K562 cells ought to be independent of p53 and p16-pRb pathways. Indeed, no change in the expression of the typical senescence-associated premalignant cell markers in the DOX-induced senescent K562 cells was found. MicroRNA profiling revealed upregulated miR-375 in DOX-induced senescent K562 cells. Treatment with miR-375 inhibitor was able to reverse the proliferation ability suppressed by DOX (p<0.05) and overexpression of miR-375 suppressed the normal proliferation of K562 cells. Upregulated miR-375 expression was associated with downregulated expression of 14-3-3zeta and SP1 genes. Autophagy was also investigated since DOX treatment was able to induce cells entering senescence and eventually lead to cell death. Among the 24 human autophagy-related genes examined, a 12-fold increase of ATG9B at day 4 and a 20-fold increase of ATG18 at day 2 after DOX treatment were noted. Conclusions/Significance This study has demonstrated that in the absence of p53 and p16, the induction of senescence by DOX was associated with upregulation of miR-375 and autophagy initiation. The anti-proliferative function of miR-375 is possibly exerted, at least in part, by targeting 14-3-3zeta and SP1 genes.


International Journal of Hematology | 2004

Comparison of a Combination Ferrous Fumarate Product and a Polysaccharide Iron complex as Oral Treatments of Iron Deficiency Anemia: A Taiwanese Study

Ta-Chih Liu; Shen-Fung Lin; Chao-Sung Chang; Wen-Chi Yang; Tyen-Po Chen

Despite efforts to improve iron supplements for iron deficiency anemia, there is no consensus on products that balance efficacy, safety and tolerability, and cost. Ferrous products are effective, but they are associated with more gastrointestinal side effects than ferric products. Ferric products tend to have lower absorption. We present results from a 12-week study that ran domized 72 people with uncomplicated iron deficiency anemia to receive a ferrous iron supplement (Ferall, a combination of ferrous fumarate with ascorbic acid, folic acid, and cyanocobalamin) or a ferric iron polysaccharide complex (Niferex, ferro-glycine sulfate) plus ascorbic acid. The ferrous product was significantly more effective, the primary and secondary endpoints including changes in levels of hemoglobin and serum ferritin. There was a slightly higher frequency of gastrointestinal side effects in patients taking the ferrous product, but both supplements were well tolerated. No participant withdrew from the study because of side effects. We concluded that the ferrous product is safe and effective for use in uncomplicated iron deficiency anemia. The lack of direct comparison between single-agent ferrous fumarate and the combination ferrous product limited interpretation of results in terms of possible effects due to other components, such as ascorbic acid.


Scandinavian Journal of Infectious Diseases | 2006

Acute Q fever with Hemophagocytic Syndrome: Case Report and Literature Review

Tun-Chieh Chen; Ko Chang; Po-Liang Lu; Yi-Chang Liu; Yen-Hsu Chen; Hsiao-Cheng Hsieh; Wen-Chi Yang; Wei-Ru Lin; Jih-Jin Tsai; Sheng-Fung Lin

Hemophagocytic syndrome is a rare complication of acute Q fever. We reported the case of 26-year-old man with fever, chills, severe headache, non-productive cough and progressive thrombocytopenia. Bone marrow aspirate revealed hemophagocytosis. We discussed the differences among the three previous reported cases and the possible mechanisms of hemophagocytic syndrome.


BioMed Research International | 2015

Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma

Wen-Chi Yang; Sheng-Fung Lin

Multiple myeloma (MM) is a hematological malignancy that remains incurable because most patients eventually relapse or become refractory to current treatments. Although the treatments have improved, the major problem in MM is resistance to therapy. Clonal evolution of MM cells and bone marrow microenvironment changes contribute to drug resistance. Some mechanisms affect both MM cells and microenvironment, including the up- and downregulation of microRNAs and programmed death factor 1 (PD-1)/PD-L1 interaction. Here, we review the pathogenesis of MM cells and bone marrow microenvironment and highlight possible drug resistance mechanisms. We also review a potential molecular targeting treatment and immunotherapy for patients with refractory or relapse MM.


Annals of Hematology | 2012

Cytomegalovirus infection and disease after allogeneic hematopoietic stem cell transplantation: experience in a center with a high seroprevalence of both CMV and hepatitis B virus

Yi-Chang Liu; Po-Liang Lu; Hui-Hua Hsiao; Chao-Sung Chang; Ta-Chih Liu; Wen-Chi Yang; Sheng-Fung Lin

Cytomegalovirus (CMV) infection and disease are important concerns after allogeneic hematopoietic stem cell transplantation (allo-HSCT). The similarity of hepatitis B virus (HBV) and CMV with regards to their chronic viral persistence and potential reactivation at the time of impaired cellular immunity has raised clinicians’ interest in the occurrence and association between them among patients receiving allo-HSCT; however, only limited data have been obtained from a high seroprevalence region of both CMV and HBV. We monitored 117 adult allo-HSCT patients with both CMV polymerase chain reaction and pp65 antigenemia assay weekly until day 100. In 91.8% of our cases, donors and recipients were both CMV seropositive, and 13.7% of the patients were positive for HBV surface antigen. The incidences of CMV infection and disease were 45.3% and 6.8%, respectively. Grade II–IV acute graft-versus-host disease and anti-thymocyte globulin-containing conditioning regimen were associated with an increased risk of CMV infection in a multivariate analysis (hazard ratio 3.02, 95% CI 1.68–5.42, p < 0.001 and hazard ratio 5.29, 95% CI 2.57–10.8, p < 0.001). No survival disadvantage was found in patients who developed CMV infection (p = 0.699) and CMV disease (p = 0.093). No clinically significant HBV reactivation was found, and the underlying HBV infection in donors or recipients before allo-HSCT did not increase the risk of CMV infection and CMV disease and did not influence survival after allo-HSCT.


BMC Cancer | 2012

Herpes zoster is associated with an increased risk of subsequent lymphoid malignancies - A nationwide population-based matched-control study in Taiwan

Yi-Chang Liu; Yi-Hsin Yang; Hui-Hua Hsiao; Wen-Chi Yang; Ta-Chih Liu; Chao-Sung Chang; Ming-Yu Yang; Pai-Mei Lin; Jui-Feng Hsu; Pi-Yu Chang; Sheng-Fung Lin

BackgroundInfectious agents have been shown to contribute to the development of lymphoid malignancies. The different distribution of lymphoid malignancies in Asian and Western populations suggests possibly different etiologies in Asian populations. Herpes zoster infection, commonly seen in immunocompromised persons, has been reported to be associated with lymphoid malignancies in retrospective case–control studies from Western populations, but the results are controversial and large-scale prospective studies from Asian populations are lacking.MethodsA nationwide population-based matched-controlled prospective study on Taiwanese patients was performed using the National Health Insurance Research Database from 1996 to 2007. Herpes zoster and malignancies were defined by compatible ICD-9-CM (International Classification of Disease, 9th Revision, Clinical Modification) codes. Patients who had been diagnosed with any malignancies before herpes zoster, with known viral infections including human immunodeficiency virus, and duration from herpes zoster to diagnosis of malignancies less than 6 months were excluded.ResultsOf 42,498 patients with herpes zoster prior to the diagnosis of any malignancies, the cumulative incidence for lymphoid malignancies was 0.11% (n = 48), compared with 0.06% (n = 106) in 169,983 age- and gender-matched controls (univariate hazard ratio (HR): 1.82, 95%CI: 1.29-2.55). The most common lymphoid malignancy was non-Hodgkin’s lymphoma (60.4%, n = 29), followed by multiple myeloma (27.1%, n = 13). Risk for developing lymphoid malignancies is significantly higher in herpes zoster patients (log rank P = 0.005). After adjusting for presence of any comorbidities in Charlson comorbidity index, time-dependent covariate for herpes group, and income category using Cox proportional hazard regressions, herpes zoster patients had an increased risk of developing lymphoid malignancies (adjusted HR: 1.68, 95%CI: 1.35-2.42, P = 0.0026), but did not have an increased risk of developing non-lymphoid malignancies (adjusted HR: 1.00, 95%CI: 0.91-1.05, P = 0.872).ConclusionPreceding herpes zoster infection is an independent risk marker for subsequent lymphoid malignancies in Taiwanese subjects. Further studies are warranted for pathogenesis exploration and preventive strategies in Asian populations.


Kaohsiung Journal of Medical Sciences | 2011

Additional chromosome abnormalities in chronic myeloid leukemia

Hui-Hua Hsiao; Yi-Chang Liu; Hui-Jen Tsai; Jui-Feng Hsu; Wen-Chi Yang; Chao-Sung Chang; Sheng-Fung Lin; 蕭惠樺; 劉益昌; 蔡慧珍; 許瑞峰; 楊文祺; 張肇松; 林勝豐

The Philadelphia (Ph) chromosome and/or Breakpoint cluster region‐Abelson leukemia virus oncogene transcript are unique markers for chronic myeloid leukemia (CML). However, CML demonstrates heterogeneous presentations and outcomes. We analyzed the cytogenetic and molecular results of CML patients to evaluate their correlation with clinical presentations and outcome. A total of 84 newly diagnosed CML patients were enrolled in the study. Patients were treated according to disease status. Bone marrow samples were obtained to perform cytogenetic and molecular studies. Clinical presentations, treatment courses, and survival were reviewed retrospectively. Among 84 patients, 72 had chronic phase and 12 had accelerated phase CML. Cytogenetic study showed 69 (82.1%) with the classic Ph chromosome, 6 (7.2%) with a variant Ph chromosome, and 9 (10.7%) with additional chromosome abnormalities. Fifty‐four (64.3%) cases harbored b3a2 transcripts, 29 (34.5%) had b2a2 transcript, and 1 had e19a2 transcript. There was no difference in clinical presentations between different cytogenetic and molecular groups; however, additional chromosome abnormalities were significantly associated with the accelerated phase. Imatinib therapy was an effective treatment, as measured by cytogenetic response, when administered as first‐ and second‐line therapy in chronic phase patients. Survival analysis showed that old age, additional chromosome abnormalities, high Sokal score, and no cytogenetic response in second‐line therapy had a significant poor impact (p < 0.05). In conclusion, we presented the cytogenetic and molecular pattern of CML patients and demonstrated that the additional chromosome abnormality was associated with poor outcome.


Journal of Clinical Oncology | 2011

Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, With Unusual Clinical Presentation of Bluish-Reddish Multicolored Rainbow Pattern

Chiung-Tang Huang; Wen-Chi Yang; Yi-Chang Liu; Sheng-Fung Lin

Case Report To our knowledge, we report, for the first time, the clinical findings of a 40-year-old woman with a large tumor approximately 20 15 cm in size that appeared as a bluish-reddish multicolored rainbow pattern over the back area. Biopsy revealed primary cutaneous diffuse large B-cell lymphoma, leg type (PCLBCL LT). She first came to our hospital because of the large tumor and also due to a fever occurring off and on for 2 weeks. Other associated symptoms and signs were general malaise and body weight loss of 5 kg in 1 month. She denied any underlying disease. The characteristics of the huge tumor were purple-black patch with erythematous papules and central erosion with bluish-reddish multicolored rainbow pattern approximately 20 15 cm (Fig 1). She described the tumor as being approximately 5 cm for about 3 years, but noted rapid growth of up to 20 cm over a 3-month period. Initial laboratory findings revealed a WBC count of 3,600/ L, hemoglobin of 8.1 g/dL, and platelets of 321,000/ L. The renal and liver functions were normal. The tumor biopsy revealed diffuse lymphoid of a mediumto large-sized nature infiltrated from papillary dermis to deep reticular dermis and pleomorphic nuclei with coarse chromatin and scant to moderate cytoplasm (original magnification, 400; Fig 2, arrow). Immunohistochemical analysis revealed that the neoplastic cells were positive for CD20 (original magnification, 400; Fig 3, arrow), Bcl-2, and Ki-67 (data not shown), but negative for CD3, CD56, CD15, and ALK-1. The diagnosis was primary cutaneous diffuse large B-cell lymphoma, leg type. Positron emission tomography revealed increased fluorodeoxyglucose avidity over the back area (Fig 4; arrows). Bone marrow biopsy revealed primary cutaneous B-cell lymphoma with bone marrow invasion (data not shown), and immunohistochemical findings were positive for CD20. There was no other systemic organ involvement. The patient began receiving systemic chemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone. After two cycles of treatment, the large tumor showed gradual improvement.

Collaboration


Dive into the Wen-Chi Yang's collaboration.

Top Co-Authors

Avatar

Sheng-Fung Lin

Kaohsiung Medical University

View shared research outputs
Top Co-Authors

Avatar

Yi-Chang Liu

Kaohsiung Medical University

View shared research outputs
Top Co-Authors

Avatar

Hui-Hua Hsiao

Kaohsiung Medical University

View shared research outputs
Top Co-Authors

Avatar

Chao-Sung Chang

Kaohsiung Medical University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jui-Feng Hsu

Kaohsiung Medical University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Ta-Chih Liu

Kaohsiung Medical University

View shared research outputs
Top Co-Authors

Avatar

Chiung-Tang Huang

Kaohsiung Medical University

View shared research outputs
Top Co-Authors

Avatar

Hui-Jen Tsai

National Health Research Institutes

View shared research outputs
Researchain Logo
Decentralizing Knowledge